Study identifier:D3870C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised, single-blind, placebo-controlled single-centre phase I study in healthy male volunteers to assess the safety, tolerability and pharmacokinetics of AZD2820 after single ascending doses
Healthy
Phase 1
Yes
AZD2820, Placebo
Male
90
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This is a randomised, single-blind, placebo-controlled Phase I study to investigate the safety, tolerability and pharmacokinetics after administration of single doses of AZD2820 to healthy male subjects.
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: AZD2820 | Drug: AZD2820 Subcutaneous Injection in abdomen or Thigh |
Placebo Comparator: Placebo | Drug: Placebo Subcutaneous Injection in abdomen or Thigh |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.